FDA Brief

Warning letters Drugs

FDA warning letter to

BGP, LLC

High riskIssued May 19, 2021Posted May 20, 2021Center for Drug Evaluation and Research

FDA and FTC warned BGP, LLC that its Biocence topical antiseptic is an unapproved, misbranded drug sold with COVID-19 treatment and prevention claims.

What happened

FDA and FTC reviewed www.biocence.com on February 9, 2021 and May 11, 2021, along with linked Facebook and Instagram pages. The agencies found the product labeled and promoted as an OTC drug with claims that it prevents or treats COVID-19 and other diseases, and with statements suggesting FDA approval. FDA says the product is an unapproved new drug and is misbranded.

What FDA found

  1. The product is a new drug sold without an FDA-approved application.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The labeling is false or misleading because it says the product is FDA approved or registered.

    section 502(a) of the FD&C Act, 21 U.S.C. § 352(a)
  3. The product does not meet the conditions for marketing without approval under section 505G.

    section 502(ee) of the FD&C Act, 21 U.S.C. § 352(ee)
  4. The active ingredient, Biocence Botanical Complex, was not a proposed active ingredient in the topical antiseptic rulemaking.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. § 355h(a)(3)
  5. The label claims benefits beyond a topical antiseptic, such as killing COVID-19, MRSA, H1N1, Ebola, and HIV and treating wounds.

    1994 TFM, as amended by the 2015 and 2016 proposed rules
  6. The company advertised that the product can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA tells BGP to take immediate action to stop selling the unapproved and misbranded COVID-19 products and to email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours with the steps taken, documents, and a plan to prevent recurrence. FTC separately asks for an email to rcleland@ftc.gov within 48 hours describing corrective actions.

Who should pay attention

  • consumers buying COVID-19 products online
  • retailers and marketplaces listing OTC antiseptics
  • companies making antiviral or antibacterial claims on websites and social media

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk